Introduction 41
A critical period in human pregnancy occurs during the first trimester when the 42 trophectoderm attaches to the uterine surface epithelium with subsequent invasion of 43 trophoblast cells through the decidua until they stop in the inner myometrium. Infiltration of 44 placental cells deep into the uterus is essential, because trophoblast moves towards, and 45 then transforms, the spiral arteries to establish the fetal blood supply line. A range of 46 evidence points to defects in placental/uterine interactions underpinning a spectrum of 47 pregnancy disorders, such as pre-eclampsia, unexplained stillbirth, fetal growth restriction 48 and recurrent miscarriage (Brosens, 2011) . Disordered interactions between trophoblast and 49 uterus may also contribute to primary infertility and failed IVF, given the epidemiological 50 overlap between all these conditions (Basso, 2003) . 51
52
We hypothesise here that part of the regulation of placentation results from local immune 53 recognition of trophoblast by decidual leukocytes, an idea that arose from two observations. 54
First, cellular interactions in the decidua occur between cells from two genetically different 55 individuals (allogeneic cells). Secondly, the crucial role that the decidua plays in the 56 regulation of placentation is obvious from studying pregnancy disorders that arise when 57 decidua is absent: in this scenario, known as placenta percreta/accreta, trophoblast invades 58 relentlessly through the uterus, a situation that often occurs when the placenta forms over a 59 previous caesarian section scar. 60 61 Key features of the immune system are specificity and memory. In terms of human 62 pregnancy, epidemiological and genetic studies of pre-eclampsia do point to 'partner 63 specificity' (Lie, 1998) . Furthermore, the protective effect of a first pregnancy against pre-64 eclampsia in subsequent pregnancies with the same father might be interpreted as 'memory' 65 (Trogstad, 2001) . A further important point is the high incidence (~25%) of pre-eclampsia in 66 oocyte donation pregnancies (Levron, 2014) . In this situation the embryo is derived from two 67 allogeneic individuals and shares no 'self' with the mother. This situation is therefore 68 analogous to a mother being exposed to two rather than one paternal genomes. There are 69 no comparable studies indicating that particular fathers might be 'risky' in recurrent 70 miscarriage or primary infertility. 71 4 72
uNK cells and trophoblast HLA-C 73
Which immune cells and target antigens might be involved in preeclampsia? Our focus is on 74 uterine Natural Killer cells (uNK), because they are the dominant population (~70% of 75 leucocytes) present during early placentation and have receptors that can bind to 76 trophoblast ligands. Although T cells, the effector immune cells responsible for rejection of 77 organ grafts, are also present in decidua (~10-30% of leukocytes), there is no evidence to 78 date that pregnancy failure in humans ever results from T cell 'rejection' of the placenta 79 (Moffett & Colucci, 2014) . Indeed, no molecular recognition system whereby maternal T 80 cells might recognize and target trophoblast has yet been described convincingly. In contrast, 81 uNK are distinctive immune cells that accumulate in large numbers around the infiltrating 82 extravillous trophoblast (EVT) cells in the decidua basalis and they have a range of receptors 83 that can bind to ligands on EVT (Sharkey, 2008; Xiong, 2013) . The uNK receptors of particular 84
interest are called Killer Immunoglobulin-like Receptors (KIRs) and they are a highly 85 polymorphic family of genes with great variation between different individuals. Some 86 members of the KIR gene family bind HLA-C molecules, the only polymorphic HLA class I 87 molecule expressed by EVT ( Figure 1 ). Thus, in any pregnancy, individual women vary in 88 comparison with other women in respect of the KIR genes that they have inherited and that 89 are expressed by their uNK cells. The paternally-derived HLA-C allele expressed on the 90 trophoblast will also differ in each pregnancy (even when from the same father) depending 91 on which of the two paternal HLA-C alleles the fetus has inherited ( Figure 2 ). 92
93
The possibility that the combinations of two variable gene systems, one in the mother and 94 one in her fetus, might subtly determine the outcome of interactions between trophoblast 95 and uNK cells led to initial studies on pre-eclampsia, a disorder with clear underlying defects 96 in placentation. Pre-eclampsia is associated with certain combinations of maternal KIR/fetal 97 HLA-C genetic variants in cohorts of both Africans and Europeans. Since then, studies of small 98 cohorts of women affected by recurrent miscarriage and fetal growth restriction have 99 indicated a similar relationship. More recently, analysis of maternal KIR and fetal HLA-C 100 variants in normal pregnancies resulting in a range of different birth weights has indicated 101 that selective pressures on these two gene systems are operating to keep human birth 102 weight between two extremes -both associated with high fetal and maternal mortality and 103 5 morbidity (Hiby, 2014) . Indeed, these KIR and HLA gene families are likely to be subjected to 104 balancing or stabilizing selection via human birth weight, as the two extremes of the normal 105 range are both deleterious (Karn, 1951) . where KIRs bind to the HLA-C molecules, the KIR-binding C1 or C2 epitope. There are 2 KIRs 119 that bind to C2 epitopes, inhibitory KIR2DL1 and activating KIR2DS1. Only one KIR binds to 120 C1 epitopes and imparts a weakly inhibitory signal (KIR2DL2/3). 121
122
Our results show that when women, who have inherited two KIR A haplotypes (known as a 123 KIR AA genotype), encounter trophoblast expressing a C2 epitope, then trophoblast is more 124 likely to fail to establish a good maternal blood supply to the placenta, with the outcome of 125 poor fetal growth and an increased risk of pre-eclampsia. Furthermore, the risk seems 126 greater if the fetal C2 is derived from a paternal rather than a maternal HLA-C2 allele. The 127 reasons for this are unknown and it is also unclear why the effect of paternal C1 epitopes 128 inherited by the fetus is neutral. two KIR A haplotypes (KIR AA genotype) only has KIR genes that encode receptors that will 134 impart a strong inhibitory signal to uNK cells. The likely candidate KIR responsible for this 135 6 deleterious effect on the KIR A haplotype is KIR2DL1 because it binds strongly and specifically 136 to C2 epitopes of HLA-C. In Europeans, when there is a pregnancy with a paternally-derived 137 HL-A C2 epitope, the mother is protected when she has a KIR B haplotype that contains the 138 activating KIR for C2 epitopes, KIR2DS1. There is thus a protective effect in this combination, 139 because, when a paternal C2 epitope is present, the strong inhibitory signal from KIR2DL1 to 140 uNK cells is counter balanced by an activating signal. 141 142
Pre-eclampsia 143
The largest cohorts studied to date are from pregnant white British women with controls 144 selected from the same hospitals at the same time, who had never been pregnant before 145 and had a normal full term pregnancy (Hiby, 2004 (Hiby, , 2010 . For women developing pre-146 eclampsia there is an association of a maternal KIR AA genotype with a paternal HLA-C C2 147 epitope. These findings associated with risk of pre-eclampsia have now been confirmed in a 148 smaller cohort of Ugandan women, but interestingly the protective KIR region is different in 149
Africans compared with Europeans (Nakimuli, 2015) . Further large cohorts are needed in 150
European, Asian and African populations to provide further validation. This is essential since 151 the KIR and HLA regions have evolved rapidly with the frequencies of KIR A haplotypes and 152
HLA-C alleles carrying the C2 epitope varying in different populations with a striking inverse 153 correlation between the two. For example, Japanese have increased frequencies of KIR A 154 haplotypes, but a reduced frequency of HLA-C alleles carrying the C2 epitope compared with 155
Europeans (Hiby, 2004) . This situation is likely to have evolved to avoid too many 156 pregnancies with this risky combination given that KIR and HLA-C are located on separate 157 chromosomes and segregate independently. This observation also gives rise to speculation 158 that couples of mixed ethnicity might be more or less at risk of pre-eclampsia. However, 159 large cohorts would be needed to test this. Although one study found that the incidence of 160 pre-eclampsia in 324 Japanese women with European partners was not higher than in 161 Japanese women with Japanese partners (Saito, 2006) , this study was only based on 162 assumed frequencies of genotypes and no KIR and HLA-C genotyping of the couples was 163 performed (Moffett, 2006) . The incidence of the KIR AA genotype is 60% in Japanese women. 164
HLA-C2 group frequencies are 32% in Europeans but only 9% in Japanese. Around 5 of 324 165
(1.5%) Japanese-European couples had pre-eclampsia . Given this sample size, the authors 166 have <50% power to detect any significant difference (at p < 0.05) in the frequency of pre-7 eclampsia between Japanese-European couples compared with Japanese-Japanese couples 168
for an odds ratio as large as 3. Therefore, the conclusions drawn by Saito et al. (2006) are 169 untenable due to the lack of power to recognize any effect, regardless of the direction. The 170 study is thus statistically flawed. 171 172 If our own genetic results hold up in more powered studies, is there any role in the future for 173 prediction and prevention of pre-eclampsia? First the accuracy of the genetic prediction 174 needs to be improved. In addition to variation in numbers of KIR genes a woman 175 inherits, there is also allelic variation at individual KIR loci. KIR2DL1 (the inhibitory KIR 176 for C2 epitopes) has four common alleles segregating in Europeans, whose products 177 differ in expression level, binding avidity/affinity and signaling. The different HLA-C 178 allotypes that all bear C2 epitopes may also bind differentially to different KIR allotypic 179 variants. These two levels of allelic variation could explain the low accuracy, which might 180 also be improved by combining the genetic information with models based on uterine 181 artery Doppler ultrasound and maternal factors (Yu, 2005) . 182
Of immediate concern is the risk to oocyte donation recipients and surrogate mothers 183 who are reported to have such a high risk of pre-eclampsia, which could be linked to their 184 higher risk of exposure to foreign C2 (64% versus 40% in a normal pregnancy). Ideally one 185 might predict that women who have a KIR AA genotype should only be offered C1C1 oocytes 186 and should not volunteer for surrogacy unless the donated embryo is also C1C1. Although 187 this is a low risk, low cost intervention, confirmation that the pre-eclampsia cases are indeed 188 associated with fetal C2 is first needed. In such a study, and assuming a 25% risk of pre-189 eclampsia in oocyte donations versus 10% in other women undergoing assisted 190 reproduction, 750 cases would be needed to detect with 90% power a significant (<0.05, 191 two-sided) risk of pre-eclampsia associated with maternal KIR AA and fetal HLA-C2. 192
193

Recurrent Miscarriage 194
There are several studies of maternal KIR genes in recurrent miscarriage but the findings are 195 conflicting with no clear results (Moffett, 2009 ). There are many problems with these studies typing into the clinic until these issues are resolved. Large well-characterised cohorts are 201 needed with good controls to define clearly whether there are any particular KIR genotypes 202 associated with failure of trophoblast to establish a blood supply in the first trimester. 203 204
Infertility/IVF 205
There is only one study on KIR genotypes in women with infertility and failed IVF, and it 206 points to a lower live birth rate in women with the KIR AA genotype (Alecsandru, 2014) . 207
Further studies would be of interest as it is not clear whether the failure could in some cases 208 occur in the early days post-implantation or from failure of attachment of the blastocyst to 209 the surface epithelium. In the latter situation, uNK cells are unlikely to play a part. 210 211
Genotyping KIR and HLA in other clinical scenarios 212
The NK cells that are present in blood participate in responses to infectious agents and 213 cancerous cells and modify the outcome of haematopoietic cell transplantation. 214
Interestingly, genotyping for KIR and HLA is also being investigated in these areas of medicine 215 to improve current treatments. For example, genotyping of HLA-C and KIR significantly 216 improves the prediction of responses to treatment in patients with chronic hepatitis C and 217 hepatitis B virus infection (Suppiah, 2011; Stelma, 2016) . Other studies in haplo-identical 218 (half-HLA mismatched) haematopoietic cell transplantations for myeloid leukemia have 219
shown that there is a better outcome if the donor has a KIR B haplotype (Cooley, 2014) . 220
221
The Future 222
Can these results be translated yet to any clinical situation in reproduction? In short, the 223 answer must be 'Not Yet'. There are many reasons for this: 224
Most of the cohorts studied are small. Large numbers are required for sufficiently 225 powered studies that involve two individuals, two complex gene systems, and conditions 226 of heterogeneous aetiologies influenced by other genetic and environmental 227 contributions. To give one example: a cohort of 3943 pregnancies would be needed to 228 detect with 90% power a significant risk (<0.05, two-sided) of reduced birth weight (120g 229 less than the average 3350g ± 450g) linked to a combination of a given KIR allele and a 230 9 given fetal HLA-C allele found in about 4% of the pregnancies. In the current state of 231 knowledge, if maternal KIR/fetal HLA-C genetic combinations were used for screening, 232
considering an incidence of pre-eclampsia of 4%, we would have: 233
If the positive test result is for the women to be KIR AA (OR 1.54), the sensitivity (true 234 positive rate) would be 36.92% and the specificity (true negative rate) 72.50%. 235
If the positive test result is for the women to be KIR AA with a paternal HLA-C2 allele in 236 the fetus (OR 2.02), the sensitivity (true positive rate) would be 43.75% and the 237 specificity (true negative rate) 72.20%. 238
Therefore the performance of these screening tests, in those configurations, would not 239 be useful to identify women at risk of pre-eclampsia. 240
• Cases and controls must be very carefully matched particularly with regard to ethnicity 241 and genetic admixture because of the great diversity of KIR and HLA genes across 242 different populations. 243
• Independent studies in different populations across the world are needed to replicate 244 the original findings. 245
• The clinical characteristics should be identified carefully. For example, in women 246 affected by recurrent miscarriage/failed IVF, all known underlying causes for problems in 247 pregnancy must be excluded. For pre-eclampsia, preexisting hypertension, renal disease, 248 and placental malaria, must be ruled out. In studying true fetal growth restriction , the 249 gestational age is needed and cases with infectious/genetic or other causes of low birth 250 weight must be omitted. 251
• The population to select as ideal controls is not immediately obvious. Ideally women 252 with a history of normal pregnancies reaching a gestation of >38 weeks, with birth 253 weights in the middle of the normal range, no miscarriages or ectopic pregnancies would 254 be used. This would correspond to a case-control design with extreme phenotypes, 255 which would increase power. Cases and controls should still be matched in terms of 256 unrelated diseases. Earlier studies have used normal first pregnancies. 257
• A family-based design would also help avoid confounding factors in order to identify the 258 genes responsible for defective placentation in pre-eclampsia. 259
• The KIR and HLA typing should be done in conjunction with laboratories devoted to 260 tissue typing for transplantation in hospitals or to KIR and HLA diversity in a research 261 setting. The UCLA International Cell Exchange offers validation for KIR typing and all 262 research laboratories should be a part of this (http://www.hla.ucla.edu/cellDna.htm; 263 Chazara, 2015) . 264
• Analysis of KIR variation has been a challenge given the huge diversity. There is a 265 growing consensus that, because of the tight Linkage Disequilibrium (LD) of KIR, 266 characteristic of the telomeric (t) and centromeric (c) regions of KIR A and B haplotypes, 267
it is better to first use a broad distinction between KIR AA and all other genotypes and 268 then between these centromeric and telomeric (cA, tA, cB and tB) regions. This strategy 269 avoids implicating any KIR that may only be 'carried' in LD and not be a risk itself. 270
271
If, from these studies, the associations of KIR and HLA-C variants with reproductive problems 272 turn out to be robust, in the future it might be feasible to select sperm from donors who are 273 C1C1 homozygous, because in our cohorts we have always found a neutral effect of C1C1 274 babies whatever the mother's KIR genotype. The frequency in the UK of C1C1 men is ~36%. 275
276
Conclusion 277
The KIR/HLA system is likely to be associated with the primary stage in the pathogenesis of 278 pre-eclampsia/defective placentation and is not related to the systemic symptoms. In 279 keeping with this, similar KIR/HLA-C associations are found with recurrent miscarriage and 280 fetal growth restriction . This is one end of the spectrum (in terms of birth weight or low 281 placental efficiency), with large babies at the other end. In this scenario birth weight is 282 acting as a proxy for either a 'good' or 'bad' placenta. We have described how immune 283 system genes are candidates for balancing the system and keeping the birth weight optimum 284 for the population overall. Rarer combinations are found at the two extremes of birth 285 weight. Obviously there are multiple other genetic, nutritional and environmental influences 286 operating that will modify how uNK cells function in each pregnancy. By bringing together 287 high-resolution genotyping with new approaches to understand the biology of uNK-288 trophoblast interactions, we will eventually make progress towards predicting and 289 preventing complications of pregnancy. 290 291
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